Abstract
Anticoagulant drugs are traditionally administered for the prevention and treatment of thrombosis. Besides multi-targeted, traditional anticoagulants, such as coumarins or heparins, the search for the optimal antithrombotic efficacy to bleeding risk ratio has prompted the development of a novel armamentarium of anticoagulant drugs, which is expected to be introduced in the market. These emerging drugs are mainly targeted to suppress the propagation of the coagulation cascade (thrombin burst), by direct thrombin inhibition or selective inhibition of activated factor X. Therefore, thrombin or activated factor X antagonists would produce an efficient anticoagulation while minimizing the risk of bleeding, the most common adverse events of conventional anticoagulants. No routine monitoring, favorable form of administration and better compliance are additional advantages of these innovative drugs, which are already in advanced development or already licensed for clinical use. The aim of this article is to provide an overview on the mechanisms of action, clinical applications, cost-effectiveness and side effects of these emerging anticoagulant strategies.
Keywords: Direct thrombin inhibitors, venous thromboembolism (VTE), Fondaparinux, Rivaroxaban, Heparin
Current Vascular Pharmacology
Title: Antagonists of Activated Factor X and Thrombin: Innovative Antithrombotic Agents.
Volume: 5 Issue: 2
Author(s): Massimo Franchini and Giuseppe Lippi
Affiliation:
Keywords: Direct thrombin inhibitors, venous thromboembolism (VTE), Fondaparinux, Rivaroxaban, Heparin
Abstract: Anticoagulant drugs are traditionally administered for the prevention and treatment of thrombosis. Besides multi-targeted, traditional anticoagulants, such as coumarins or heparins, the search for the optimal antithrombotic efficacy to bleeding risk ratio has prompted the development of a novel armamentarium of anticoagulant drugs, which is expected to be introduced in the market. These emerging drugs are mainly targeted to suppress the propagation of the coagulation cascade (thrombin burst), by direct thrombin inhibition or selective inhibition of activated factor X. Therefore, thrombin or activated factor X antagonists would produce an efficient anticoagulation while minimizing the risk of bleeding, the most common adverse events of conventional anticoagulants. No routine monitoring, favorable form of administration and better compliance are additional advantages of these innovative drugs, which are already in advanced development or already licensed for clinical use. The aim of this article is to provide an overview on the mechanisms of action, clinical applications, cost-effectiveness and side effects of these emerging anticoagulant strategies.
Export Options
About this article
Cite this article as:
Franchini Massimo and Lippi Giuseppe, Antagonists of Activated Factor X and Thrombin: Innovative Antithrombotic Agents., Current Vascular Pharmacology 2007; 5 (2) . https://dx.doi.org/10.2174/157016107780368325
DOI https://dx.doi.org/10.2174/157016107780368325 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Human Internal Jugular Valve M-mode Ultrasound Characterization
Current Neurovascular Research Proteins in Pharmacology: Restrictions, Challenges and Opportunities
Current Medicinal Chemistry Opportunities Offered by Chitosan-Based Nanotechnology in Mucosal/ Skin Drug Delivery
Current Topics in Medicinal Chemistry Low-Molecular-Weight-Heparins: A Review of Literature
Vascular Disease Prevention (Discontinued) Changes in Markers of Bone Metabolism Following Surgery
Recent Patents on Biomarkers Hyperhomocysteinaemia: A Critical Review of Old and New Aspects
Current Drug Metabolism Epigenetics: New Concepts of Old Phenomena in Vascular Physiology
Current Vascular Pharmacology Pharmacological Interventions and Rehabilitation Approach for Enhancing Brain Self-repair and Stroke Recovery
Current Neuropharmacology New Developments in Therapeutic Agents for Legionnaires Disease
Anti-Infective Agents in Medicinal Chemistry Pharmacokinetics of Antifungal Agents in Neonates and Young Infants
Current Medicinal Chemistry Calcium Metabolism and Oxidative Stress in Bone Fractures: Role of Antioxidants
Current Drug Metabolism Clinical PET Imaging of Insulinoma and Beta-Cell Hyperplasia
Current Pharmaceutical Design Targeted Drug Delivery: Trends and Perspectives
Current Drug Delivery Nutritional Requirements for Maternal and Newborn Health
Current Women`s Health Reviews Emerging Vascular Risk Factors in Women: Any Differences from Men?
Current Medicinal Chemistry Pulmonary Hypertension and Right Ventricular Dysfunction in Chronic Lung Diseases: New Pathobiologic Concepts
Current Respiratory Medicine Reviews Cigarette Smoking and Angiogenesis: What is the Role of Endothelial Progenitor Cells?
Current Angiogenesis (Discontinued) Anesthetic Pharmacology and Perioperative Considerations for Heart Transplantation
Current Clinical Pharmacology Phage Choice, Isolation, and Preparation for Phage Therapy
Current Pharmaceutical Biotechnology Enhancing the Quality of Laboratory Results in Clinical Trials
Applied Clinical Research, Clinical Trials and Regulatory Affairs